BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 26414730)

  • 1. Why focus on uric acid?
    Johnson RJ
    Curr Med Res Opin; 2015; 31 Suppl 2():3-7. PubMed ID: 26414730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gout and cardiovascular risk].
    Němec P
    Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of serum uric acid on blood-pressure lowering treatment.
    Grassi G
    Curr Med Res Opin; 2017 Nov; 33(sup3):15-19. PubMed ID: 28952389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
    Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
    Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum uric acid and the risk of cardiovascular and renal disease.
    Borghi C; Rosei EA; Bardin T; Dawson J; Dominiczak A; Kielstein JT; Manolis AJ; Perez-Ruiz F; Mancia G
    J Hypertens; 2015 Sep; 33(9):1729-41; discussion 1741. PubMed ID: 26136207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperuricemia, urate deposition and the association with hypertension.
    Mancia G; Grassi G; Borghi C
    Curr Med Res Opin; 2015; 31 Suppl 2():15-9. PubMed ID: 26414732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of Target Serum Uric Acid Levels and Factors Associated with Therapeutic Failure among Japanese Men Treated for Hyperuricemia/Gout.
    Katayama A; Yokokawa H; Fukuda H; Ono Y; Isonuma H; Hisaoka T; Naito T
    Intern Med; 2019 May; 58(9):1225-1231. PubMed ID: 30626825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uric acid lowering therapy in cardiovascular diseases.
    Volterrani M; Iellamo F; Sposato B; Romeo F
    Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and renal effects of hyperuricaemia and gout.
    Viazzi F; Leoncini G; Pontremoli R
    Reumatismo; 2012 Jan; 63(4):253-62. PubMed ID: 22303532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.
    Pontremoli R
    Curr Med Res Opin; 2017 Nov; 33(sup3):27-32. PubMed ID: 28952388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
    Keenan RT
    Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.
    Liu S; Perez-Ruiz F; Miner JN
    Joint Bone Spine; 2017 Mar; 84(2):183-188. PubMed ID: 27324603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
    Takahashi T; Beppu T; Hidaka Y; Hosoya T
    Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
    [No Abstract]   [Full Text] [Related]  

  • 15. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
    Levy GD; Rashid N; Niu F; Cheetham TC
    J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
    Mallat SG; Al Kattar S; Tanios BY; Jurjus A
    Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The problem of cardio-renal diseases in patients with gout.
    Ferri C
    Curr Med Res Opin; 2017 Nov; 33(sup3):9-13. PubMed ID: 28952391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
    Bakris GL; Doghramji PP; Keenan RT; Silber SH
    Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.